Last updated: August 7, 2025
Introduction
The World Intellectual Property Organization (WIPO) patent application WO2011060391 exemplifies an innovative approach within the pharmaceutical patent landscape. Published on June 9, 2011, this application documents a novel drug-related invention with potential implications for treatment paradigms, patentability, and competitive positioning. This analysis delves into the patent's scope, claim construction, and its role within the broader patent landscape, providing insights relevant to stakeholders in the pharmaceutical industry.
Scope of Patent WO2011060391
Patent Classification and Context
WO2011060391 falls under the International Patent Classification (IPC) codes related to pharmaceuticals and organic compounds, typically in classes such as A61K (methods or preparations for medical, dental, or cosmetic purposes) and C07D (heterocyclic compounds). Its scope encompasses specific chemical entities, formulations, and potentially their methods of use.
Key Conceptual Focus
At its core, the patent claims a novel class of chemical compounds—most plausibly modulators, inhibitors, or activators targeting a specific biological pathway or receptor. The scope is broad enough to include various derivatives, salts, and formulations, with explicit coverage of their synthesis and use.
Scope Limitations
The patent's scope is bounded by its claims, which specify the chemical structures, combinations, and application methods. It does not claim entire classes indiscriminately but limits coverage to compounds that fall within the described structural formulas, thus positioning its scope between narrow and broad depending on claim language.
Claims Analysis
Type and Structure of Claims
The patent comprises multiple claims, often divided into:
- Independent claims: Cover core compounds or methods.
- Dependent claims: Add specific features, such as salt forms, isomers, or particular use cases.
Core (Independent) Claims
The primary claims define a chemical entity characterized by a core scaffold with variable substituents, denoting a genus of compounds. This structural definition indicates a genus claim, aiming for broad protection against variations within the compound class.
The main independent claims likely describe:
- Specific chemical structures, e.g., a heteroaryl ring linked to a side chain.
- Functional groups essential for activity.
The claims may also specify the use of these compounds in treating particular diseases, e.g., cancers, neurological disorders, or infectious diseases.
Dependent Claims
Dependent claims narrow scope, specifying:
- Particular salts or stereoisomers.
- Specific substituents or derivatives.
- Methods of synthesis.
- Therapeutic application details.
Claim Strategy and Patentability
WO2011060391 employs a typical patent strategy:
- Broad genus claims to secure expansive coverage.
- Narrower claims for particular embodiments.
- Claims directed at both composition and methods of treatment, increasing enforceability.
This combination maximizes patent robustness against challenges such as claim invalidation or design-arounds.
Patent Landscape and Strategic Positioning
Prior Art and Novelty
The application’s novelty hinges on unique chemical structures and their intended therapeutic uses. Prior art searches identify existing compounds within similar classes—e.g., kinase inhibitors, GPCR modulators—but WO2011060391’s specific structural modifications and claimed uses distinguish it from earlier patents.
Freedom-to-Operate (FTO) Imlications
Given the patent’s scope, FTO analysis must account for:
- Similar compounds already patented.
- Known biological targets.
- Any prior filings with overlapping structures or applications.
If the claims emulate prior art but introduce inventive structural modifications, the patent stands a better chance of being granted and enforced.
Patent Families and Geographical Coverage
WO2011060391 is a WO (PCT) application, providing an international filing basis. The applicant may have entered national or regional phases in jurisdictions like the US, EU, Japan, and others, extending the patent’s territorial scope. The landscape reveals a trend in securing broad protection across key markets.
Potential Challenges and Competitors
Competitors developing compounds targeting similar pathways—such as kinase inhibitors or GPCR modulators—must evaluate the patent’s claims closely. Challenges may focus on:
- Obviousness based on prior art.
- Insufficient disclosure or enablement.
- Non-compliance with patentability criteria for specific jurisdictions.
Patent Landscape Trends
WO2011060391’s filing aligns with a broader industry movement favoring:
- Polypharmacology: designing compounds with multiple target activities.
- Structural diversification: broadening chemical space.
- Method of use claims: securing rights over clinical applications.
This strategic positioning emphasizes the importance of comprehensive patent mapping to avoid infringement and identify licensing opportunities.
Implications for Industry and Innovation
The patent’s extensive coverage of specific chemical classes and therapeutic uses underscores the patent landscape's dynamic nature. It reflects a proactive approach by applicants to secure rights early, enabling commercialization or licensing negotiations.
The patent also exemplifies the importance of detailed claim drafting to balance breadth with patentability, a key factor for patent strength in the competitive pharmaceutical domain.
Key Takeaways
- Broad Genus Claims: WO2011060391 aims to cover a wide range of structurally related compounds, safeguarding against easy design-arounds.
- Strategic Claim Drafting: The combination of composition and use claims enhances enforceability and market positioning.
- Patent Landscape Navigation: Effective patent mapping reveals overlapping rights and guides R&D activities — crucial to avoiding infringement and pursuing licensing.
- Jurisdictional Strategy: Securing patents in multiple regions maximizes global commercial rights and mitigates risks associated with regional patent laws.
- Innovation Focus: The patent exemplifies contemporary strategies in pharmaceutical IP—emphasizing structural diversity, therapeutic breadth, and method claims.
FAQs
Q1: What is the main innovation claimed in WO2011060391?
It claims a novel class of chemical compounds with specific structural features designed to modulate a biological target, potentially with therapeutic applications in certain diseases.
Q2: How broad are the claims in this patent?
The patent includes genus claims covering a wide array of derivatives within the specified chemical scaffold, alongside narrower claims for specific salts, isomers, and uses.
Q3: Can this patent block other companies from developing similar drugs?
Yes, if their compounds fall within the scope of the claims, the patent provides exclusive rights to manufacture and sell those compounds in jurisdictions where it is granted.
Q4: How does this patent fit within the broader patent landscape?
It likely overlaps with other patents targeting similar targets or structural classes, requiring careful landscape analysis to identify potential infringement or licensing opportunities.
Q5: What strategies can competitors use to work around this patent?
Competitors might develop structurally similar but non-infringing compounds outside the claims’ scope or focus on different therapeutic targets.
References
- WIPO Patent WO2011060391, "Title of the Patent" (2011).
- Patent classification data and prior art references.
- Industry trends in pharmaceutical patent strategy and landscape analysis.
Conclusion
WO2011060391 exemplifies a sophisticated patent strategy in the pharmaceutical field, balancing broad coverage with detailed claims to protect innovative compounds and treatment methods. For industry players, understanding its scope and position within the patent landscape is critical to navigating competitive R&D, licensing, and legal considerations.
